KCM
Kynam Capital Management Portfolio holdings
AUM
$929M
This Quarter Return
-3.14%
1 Year Return
-7.66%
3 Year Return
+163.82%
5 Year Return
–
10 Year Return
–
AUM
$1.52B
AUM Growth
+$1.52B
(+17%)
Cap. Flow
+$295M
Cap. Flow
% of AUM
19.44%
Top 10 Holdings %
Top 10 Hldgs %
77.36%
Holding
31
New
5
Increased
13
Reduced
5
Closed
–
Top Buys
| 1 |
Vaxcyte
PCVX
|
$106M |
| 2 |
Celldex Therapeutics
CLDX
|
$40.6M |
| 3 |
Immunocore
IMCR
|
$36.2M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$35.4M |
| 5 |
enGene Holdings
ENGN
|
$21.7M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$22.6M |
| 2 |
Vera Therapeutics
VERA
|
$5.02M |
| 3 |
Natera
NTRA
|
$3.23M |
| 4 |
Protagonist Therapeutics
PTGX
|
$2.53M |
| 5 |
Cogent Biosciences
COGT
|
$1.05M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Natera
NTRA
$23.1B
| $320M | 18.92% | 2,022,098 -20,373 | -1% | -$3.23M |
|
|
2
Vaxcyte
PCVX
$4B
| $191M | 11.31% | 2,336,796 +1,297,508 | +125% | +$106M |
|
|
3
Celldex Therapeutics
CLDX
$1.47B
| $128M | 7.56% | 5,064,207 +1,605,598 | +46% | +$40.6M |
|
|
4
Syndax Pharmaceuticals
SNDX
$1.41B
| $113M | 6.66% | 8,520,000 +2,677,075 | +46% | +$35.4M |
|
|
5
Dynavax Technologies
DVAX
$1.19B
| $83.8M | 4.95% | 6,560,835 -1,771,852 | -21% | -$22.6M |
|
6
CG Oncology
CGON
$2.04B
| $72.3M | 4.27% | 2,519,705 +748,900 | +42% | +$21.5M |
|
|
7
Cogent Biosciences
COGT
$1.69B
| $71M | 4.2% | 9,105,000 -134,731 | -1% | -$1.05M |
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $68.3M | 4.04% | 9,085,368 | – | – |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $63.8M | 3.77% | 3,326,262 +814,967 | +32% | +$15.6M |
|
|
10
Vera Therapeutics
VERA
$1.38B
| $61.7M | 3.64% | 1,457,910 -118,639 | -8% | -$5.02M |
|
11
Wave Life Sciences
WVE
$1.53B
| $60.6M | 3.58% | 4,899,497 | – | – |
|
12
Beam Therapeutics
BEAM
$1.66B
| $43.6M | 2.57% | 1,756,158 +454,073 | +35% | +$11.3M |
|
|
13
Immunocore
IMCR
$1.62B
| $36.2M | 2.14% | +1,225,576 | New | +$36.2M |
|
|
14
enGene Holdings
ENGN
$236M
| $33.2M | 1.96% | 4,994,090 +3,257,863 | +188% | +$21.7M |
|
15
Travere Therapeutics
TVTX
$1.56B
| $31.4M | 1.86% | 1,802,750 +431,239 | +31% | +$7.51M |
|
16
Liquidia Corp
LQDA
$2.38B
| $26.7M | 1.58% | 2,266,328 | – | – |
|
17
Ironwood Pharmaceuticals
IRWD
$214M
| $20.8M | 1.23% | 4,685,563 +1,000,000 | +27% | +$4.43M |
|
|
TSVT
18
DELISTED
2seventy bio
TSVT
| $17.5M | 1.03% | 5,953,825 | – | – |
|
19
Cullinan Oncology
CGEM
$445M
| $15.3M | 0.9% | +1,252,738 | New | +$15.3M |
|
|
20
Protagonist Therapeutics
PTGX
$3.67B
| $15.1M | 0.89% | 390,792 -65,577 | -14% | -$2.53M |
|
21
Tyra Biosciences
TYRA
$675M
| $7.37M | 0.44% | 530,478 +62,531 | +13% | +$869K |
|
|
BNR
22
Burning Rock Biotech
BNR
$93.6M
| $6.72M | 0.4% | 994,883 +5,666 | +0.6% | +$38.2K |
|
23
Sutro Biopharma
STRO
$72.7M
| $6.7M | 0.4% | 3,641,447 +1,575,000 | +76% | +$2.9M |
|
|
AMRN
24
Amarin Corp
AMRN
$311M
| $6.02M | 0.36% | 12,414,628 | – | – |
|
25
ProQR Therapeutics
PRQR
$237M
| $4.64M | 0.27% | +1,750,000 | New | +$4.64M |
|